Exblifep is administered as 2.5 grams (2 grams cefepime / 0.5 grams enmetazobactam) every 8 hours by intravenous (IV) infusion over 2 hours for 7 to 14 days. Dosage adjustment is recommended in patients who have an eGFR < 60 mL/min or > 130 mL/min. Fetroja...
An average eGFR varies by age, but in younger adults who are considered healthy, a range of 80-120mL/min/1.73 m2is generally normal. GFR decreases as you get older, but a reduced GFR can cause similar issues in older adults as in those who are younger. Adecrease in GFR could also b...
Stage 3a & 3b CKD: Mild to severe loss of kidney function, eGFR 30-59. Stage 4 CKD: Severe loss of kidney function, eG FR 15-29. Is GFR 94 normal? Results. A GFR of 60 or higher is in the normal range. A GFR below 60 may mean kidney disease. A GFR of 15 or lower may me...
30,31], it is unknown whether there is a signature microbiome that is maximally influenced in an ASD background. Furthermore, the molecular mechanism that regulates host-microbiota homeostasis in normal and ASD states is not known. The analyses needed to address this...
If the hapten-modified peptide is distinguished by a T-cell as a "foreign entity" TCR engagement and a downstream T-cell response with the secretion of a variety of soluble mediators is instigated (Fig. 1; left hand side). In contrast, the PI concept proposes that T-cells are activated ...
B7-H3 expression and detection methods in lung cancer with a spotlight on SCLC B7-H3 protein is down-regulated in fibroblasts, immune cells and normal tissues, while it is overexpressed in tumor tissues, including different types of lung cancer, thus becoming an interesting and promising target ...
The “stage” of your cancer is a measure of how far your cancer has spread. The “grade” of your tumor is a measure of how different the cells are from normal cells in that area. Your doctor might use tumor typing along with your “tumor grade” and your “cancer stage” to create...
1. How much decrease in eGFR is acceptable after starting ACEi or an ARB? A decrease in eGFR is commonly observed after starting an ACEi or ARB, and a decline of less than 30% is generally considered acceptable. Patients treated with ACEi or ARB should have lab tests to check for decreas...
risks. On the whole, (and as is often applicable in preclinical drug development), outputs of a single assay or endpoint rarely are “show stopping” by themselves. When considering the impact of results in later stages (go/no go decisions), integration of the various characteristics of a dr...
Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field. Many studies have provided intriguing insight into...